The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study

OBJECTIVE AND DESIGN: The aim of this double-blind, placebo-controlled, phase III CORONA clinical trial was to evaluate the efficacy and safety of IL-6 receptor inhibitor levilimab (LVL) in subjects with severe COVID-19. SUBJECTS: The study included 217 patients. The eligible were men and non-pregna...

Descripción completa

Detalles Bibliográficos
Autores principales: Lomakin, Nikita V., Bakirov, Bulat A., Protsenko, Denis N., Mazurov, Vadim I., Musaev, Gaziyavdibir H., Moiseeva, Olga M., Pasechnik, Elena S., Popov, Vladimir V., Smolyarchuk, Elena A., Gordeev, Ivan G., Gilyarov, Mikhail Yu, Fomina, Darya S., Seleznev, Anton I., Linkova, Yulia N., Dokukina, Ekaterina A., Eremeeva, Anna V., Pukhtinskaia, Polina S., Morozova, Maria A., Zinkina-Orikhan, Arina V., Lutckii, Anton A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8479713/
https://www.ncbi.nlm.nih.gov/pubmed/34586459
http://dx.doi.org/10.1007/s00011-021-01507-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8479713/
https://www.ncbi.nlm.nih.gov/pubmed/34586459
http://dx.doi.org/10.1007/s00011-021-01507-5

Ejemplares similares